BRPI0509992A - método de estabilização de sal de sódio de cefovecina desordenado - Google Patents

método de estabilização de sal de sódio de cefovecina desordenado

Info

Publication number
BRPI0509992A
BRPI0509992A BRPI0509992-7A BRPI0509992A BRPI0509992A BR PI0509992 A BRPI0509992 A BR PI0509992A BR PI0509992 A BRPI0509992 A BR PI0509992A BR PI0509992 A BRPI0509992 A BR PI0509992A
Authority
BR
Brazil
Prior art keywords
sodium salt
cluttered
stabilization method
salt stabilization
cefovecin sodium
Prior art date
Application number
BRPI0509992-7A
Other languages
English (en)
Inventor
Michael J Pikal
Renuka Devi Reddy
Evgenyi Yur Evich Shalaev
Carl Bernard Ziegler
Original Assignee
Pfizer Prod Inc
Univ Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Univ Connecticut filed Critical Pfizer Prod Inc
Publication of BRPI0509992A publication Critical patent/BRPI0509992A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

MéTODO DE ESTABILIZAçãO DE SAL DE SóDIO DE CEFOVECINA DESORDENADO. Um método para estabilizar composições farmacêuticas contendo sal de sódio de cefovecina que está em um estado amorfo ou outro estado desordenado é descrito.
BRPI0509992-7A 2004-04-22 2005-04-11 método de estabilização de sal de sódio de cefovecina desordenado BRPI0509992A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56437204P 2004-04-22 2004-04-22
PCT/IB2005/000955 WO2005102274A2 (en) 2004-04-22 2005-04-11 Method of stabilizing disordered cefovecin sodium salt

Publications (1)

Publication Number Publication Date
BRPI0509992A true BRPI0509992A (pt) 2007-10-16

Family

ID=35033440

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509992-7A BRPI0509992A (pt) 2004-04-22 2005-04-11 método de estabilização de sal de sódio de cefovecina desordenado

Country Status (10)

Country Link
US (1) US20080096858A1 (pt)
EP (1) EP1740214B1 (pt)
JP (1) JP2007533724A (pt)
AT (1) ATE374624T1 (pt)
BR (1) BRPI0509992A (pt)
CA (1) CA2563665A1 (pt)
DE (1) DE602005002742T2 (pt)
ES (1) ES2292122T3 (pt)
MX (1) MXPA06012215A (pt)
WO (1) WO2005102274A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
CN105254648B (zh) * 2015-11-13 2018-04-03 广东温氏大华农生物科技有限公司 一种头孢维星及其钠盐的合成方法
CN112843003A (zh) * 2021-03-25 2021-05-28 海南海灵化学制药有限公司 一种注射用拉氧头孢钠的冻干粉及其冻干工艺
CN115737573B (zh) * 2022-11-30 2024-02-20 杭州沐源生物医药科技有限公司 一种注射用拉氧头孢钠冻干粉剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029655A (en) * 1975-04-11 1977-06-14 Eli Lilly And Company Method of preparing stable sterile crystalline cephalosporins for parenteral administration
US4002748A (en) * 1976-01-19 1977-01-11 Eli Lilly And Company Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration
US6001997A (en) * 1990-07-24 1999-12-14 Bateson; John Hargreaves Cephalosporins and homologues, preparations and pharmaceutical compositions
US6020329A (en) * 1990-07-24 2000-02-01 Pzifer Inc. Cephaloporins and homologues, preparations and pharmaceutical compositions
GB9726343D0 (en) * 1997-12-13 1998-02-11 Auffret Anthony The use of excipients to accelerate freeze-drying
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US7378408B2 (en) * 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
BR0215070A (pt) * 2001-12-21 2004-11-09 Pfizer Prod Inc Métodos de tratamento de infecções bacterianas em cães e gatos
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
EP1656159A2 (en) * 2003-07-31 2006-05-17 Pharmacia & Upjohn Company LLC Dispersible pharmaceutical composition for treatment of mastitis and otic disorders

Also Published As

Publication number Publication date
MXPA06012215A (es) 2007-04-19
WO2005102274A3 (en) 2006-03-30
DE602005002742T2 (de) 2008-01-24
WO2005102274A2 (en) 2005-11-03
ES2292122T3 (es) 2008-03-01
EP1740214B1 (en) 2007-10-03
CA2563665A1 (en) 2005-11-03
DE602005002742D1 (de) 2007-11-15
EP1740214A2 (en) 2007-01-10
JP2007533724A (ja) 2007-11-22
ATE374624T1 (de) 2007-10-15
US20080096858A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
BRPI0713378A8 (pt) composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto
EP2018124A4 (en) SYSTEMS AND METHOD FOR STABILIZING BONE STRUCTURES
BRPI1005138A8 (pt) aparelho auditivo intra-oral
EA200970291A1 (ru) Фармацевтическая композиция, содержащая розувастатин кальция
UA108741C2 (uk) Фармацевтична композиція для екстреної контрацепції
CL2012002422A1 (es) Método para tratar artritis por lupus activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral.
BRPI0510500B8 (pt) formulação de pó seco, seu método de preparação e dispositivo de inalação de pó seco
AR053547A1 (es) Composiciones de sales anti transpirantes de aluminio o aluminio- zirconio de eficacia acrecentada que contienen sal (es) de calcio y betaina
BR112012015710A2 (pt) filtro para um artigo de fumar, artigo de fumar, utilização de um instrumento e método para aumentar a desintegração e/ou degradação de um artigo de fumar
BR112015021352A2 (pt) composições antimicrobianas
UA109786C2 (xx) Гетероциклічні сполуки як агоністи ір-рецептора
BR112014030344A2 (pt) lembretes de ciência de localização
BR112012022094A2 (pt) uso de meloxicam para o tratamento de longa duração de distúrbios renais em gatos.
BR112015014993A2 (pt) composição para higiene oral
CL2007003232A1 (es) Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas.
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
BR112012015084A2 (pt) composição farmacêutica de liberação lenta de iloperidone
BRPI0713743C1 (pt) composto, e, composição farmacêutica
BRPI0509992A (pt) método de estabilização de sal de sódio de cefovecina desordenado
BR112013005532A2 (pt) agente terapêutico para dor
BR112016014530A2 (pt) Composição para cuidado oral e uso de um copolímero de fosfato/acrilato, um agente para controle do tártaro e um veículo oralmente aceitável
BR112015013943A2 (pt) nó de comunicação, aparelho de controle, sistema de comunicação, método de processamento de pacotes, método de controle de nó de comunicação e programa
BRPI0708114B8 (pt) sal de antagonista de cd80
CR8178A (es) Sistemas de emulsion que contienen derivados de azetidina
BR112012022073A2 (pt) uso de meloxicam para o tratamento de longa duração de distúrbios musculoesqueletais em gatos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.